中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2012年
10期
781-783
,共3页
脑梗死%组织型纤溶酶原激活物%预后
腦梗死%組織型纖溶酶原激活物%預後
뇌경사%조직형섬용매원격활물%예후
Brain infarction%Tissue plasminogen activator%Prognosis
目的 探讨影响阿替普酶静脉溶栓早期疗效的因素.方法 回顾分析接受阿替普酶溶栓治疗的100例急性脑梗死患者临床数据,根据患者溶栓后24h美国国立卫生研究院神经功能缺损评分(NIHSS评分)减少是否＞3分,分为溶栓有效组和溶栓无效组,用单因素和多因素回归比较两组各临床数据的差异.结果 单因素分析结果显示溶栓后早期疗效与3个月预后相关(P=0.000),logistic分析显示溶栓前收缩压与溶栓后早期疗效显著州关(OR 1.031,95％CI1.008～1.056,P=0.009).结论 溶栓后早期疗效好者3个月的预后好.溶栓前收缩压低者的溶栓后早期疗效好.
目的 探討影響阿替普酶靜脈溶栓早期療效的因素.方法 迴顧分析接受阿替普酶溶栓治療的100例急性腦梗死患者臨床數據,根據患者溶栓後24h美國國立衛生研究院神經功能缺損評分(NIHSS評分)減少是否＞3分,分為溶栓有效組和溶栓無效組,用單因素和多因素迴歸比較兩組各臨床數據的差異.結果 單因素分析結果顯示溶栓後早期療效與3箇月預後相關(P=0.000),logistic分析顯示溶栓前收縮壓與溶栓後早期療效顯著州關(OR 1.031,95％CI1.008～1.056,P=0.009).結論 溶栓後早期療效好者3箇月的預後好.溶栓前收縮壓低者的溶栓後早期療效好.
목적 탐토영향아체보매정맥용전조기료효적인소.방법 회고분석접수아체보매용전치료적100례급성뇌경사환자림상수거,근거환자용전후24h미국국립위생연구원신경공능결손평분(NIHSS평분)감소시부＞3분,분위용전유효조화용전무효조,용단인소화다인소회귀비교량조각림상수거적차이.결과 단인소분석결과현시용전후조기료효여3개월예후상관(P=0.000),logistic분석현시용전전수축압여용전후조기료효현저주관(OR 1.031,95％CI1.008～1.056,P=0.009).결론 용전후조기료효호자3개월적예후호.용전전수축압저자적용전후조기료효호.
Objective To analyze the factors affecting on early efficacy of intravenous thrombolysis with atleplase.Methods The clinical data of 100 acute cerebral infarction patients treated by intravenous thrombolysis with atleplase were retrospectively analyzed.The patients were divided into early effective group and ineffective group,whieh assessed by National Institute of Health Stroke Scale (NIHSS) with criteria of whether there were ＞ 3 or not at 24 hours after therapy.Univariate analysis and multivariate logistic regression analysis were used to determine the differences of clinical data between the two groups.Results Univariate analysis revealed that the early improvement was significantly associated with favorable outcome at 3 month (P =0.000).Multivariate logistic analysis revealed that the systolic pressure at baseline was moderately positively associated with early improvement (OR 1.031,95％ CI 1.008-1.056,P =0.009).Conclusion Moderately lower baseline systolic pressure is associated with early improvement after thrombolytic therapy which is associated with favorable outcome at 3 month.
